ALIMENTARY TRACT: Clinical Review“Mind the Gap” An Unmet Need for New Therapy in IBDKatz, Seymour MD, FACP, MACG* † ‡ Author Information *Department of Medicine, New York University School of Medicine, New York †North Shore University Hospital, Long Island Jewish Health System, Manhasset ‡St Francis Hospital, Roslyn, NY Reprints: Seymour Katz, MD, FACP, MACG, 1000 Northern Blvd, Great Neck, NY 11021 (e-mail: [email protected]). Journal of Clinical Gastroenterology 41(9):p 799-809, October 2007. | DOI: 10.1097/MCG.0b013e318033d71d Buy Metrics Abstract Most physicians believe that the drugs they prescribe will work in their patients and thus have made little preparation for alternative strategies in the event of failure. In the treatment of inflammatory bowel disease (IBD), achieving a remission rate of 20% to 30% or a response rate of 50% to 60% is highly acceptable. This review focuses primarily on placebo-controlled trials that evaluated “usual” treatments for IBD in terms of induction and maintenance of remission, and identifies the “gaps” (ie, the percentage of patients lacking any benefit) in currently available treatments for IBD. Approximately, 40% to 60% of patients will not benefit from the available treatments, indicating a considerable unmet need for new, more effective therapies. © 2007 Lippincott Williams & Wilkins, Inc.